20 November 2017 

AorTech International plc

("AorTech" or the "Company")

Change of adviser

AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, announces the appointment of Stockdale Securities Limited as its Nominated Adviser and Broker with immediate effect.

For further information contact:

AorTech International plc                                                                            Tel: +44 (0)7730 718296 

Bill Brown, Chairman                                                                                     

Stockdale Securities Limited                                                                      Tel: +44 20 7601 6100 

Tom Griffiths/El-Hanan Lee                                                        

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA.  With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.